If you'e an insulin-dependent diabetic or know someone who is, you'll want to read this fascinating article from the February issue of Diabetes Health Magazine.
The investigative piece by reporter Daniel Trecroci examines how the six million-plus Americans who take insulin are in a quandary as leading insulin manufacturers have taken effective, less-expensive insulin medications off the market and instead began selling newer, more-pricey meds.
He also raises questions about the safety of the remaining insulin options. For example, Trecroci asks if Lantus is really all that safe and if it has long-term cancer potential.
After briefly telling the stories of two people left confused when the insulin they bought was taken off the market, reporter Trecroci raises the important issue:
...people like Hirst and Frazer [the two consumers he quoted] are beginning to think that Eli Lilly, Novo Nordisk and Sanofi-Aventis are no longer looking out for the best interests of insulin-using diabetics trying to keep in optimal control of their blood glucose. Instead, they and others feel that insulin manufacturers are mostly looking out for the bottom line."
Ah yes, when it comes to foods and meds, the bottom line always rears its ugly head and sure seems to play a much more important role than that of the health and welfare of our nation's citizens.